Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00407121 |
Recruitment Status :
Completed
First Posted : December 4, 2006
Last Update Posted : December 4, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis | Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation |
Study Start Date : | August 2006 |
Study Completion Date : | November 2006 |

- Best corrected visual acuity
- Retinal thickness by OCT
- Leakage in Fluorescein angiogram

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical Diagnose
- Patient Consent
- Chronic stage of inflammation
Exclusion Criteria:
- only eye
- age lower than 30 yo.
- Systemic condition

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407121
Mexico | |
Asociacion para Evitar la Ceguera en Mexico | |
Mexico, Distrito Federal, Mexico, 04030 |
Principal Investigator: | Veronica Kon-Jara, MD | Asociación para Evitar la Ceguera en México | |
Study Chair: | LuzElena Concha-Del Rio, MD | Asociación para Evitar la Ceguera en México |
ClinicalTrials.gov Identifier: | NCT00407121 |
Other Study ID Numbers: |
APEC-0025 |
First Posted: | December 4, 2006 Key Record Dates |
Last Update Posted: | December 4, 2006 |
Last Verified: | December 2006 |
Neovascular Membrane Uveitis Bevacizumab |
Uveomeningoencephalitic Syndrome Choroiditis Choroid Diseases Uveal Diseases Eye Diseases Uveitis, Posterior Panuveitis Uveitis Autoimmune Diseases of the Nervous System Nervous System Diseases |
Autoimmune Diseases Immune System Diseases Bevacizumab Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |